Gross Profit - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Gross Profit Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Gross Profit
zł31.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Gross Profit
-zł204k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Gross Profit
zł491.4k
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Gross Profit
zł268.7m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Gross Profit?
Gross Profit
31.6m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Gross Profit amounts to 31.6m PLN.

What is Ryvu Therapeutics SA's Gross Profit growth rate?
Gross Profit CAGR 1Y
19%

Over the last year, the Gross Profit growth was 19%.

Back to Top